AneurysmPANTHERNCT04545502
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
An observational study of Aneurysm and Dissection, run by Vascutek Ltd. at 30 sites in 6 countries.
Trial summary
The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice. Data will be collected both retrospectively and prospectively. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aneurysm, Dissection, Aortic Root Aneurysm
- What is being tested?
- Gelsoft Plus Vascular Graft, Vascular Bypass Graft and Cardiovascular Patch
- Type of treatment
- Medical device
- How many people
- 2,000 participants
- Where
- 30 sitesin 6 countries
- Study dates
- 17 Feb 2021to Jan 2037
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who require treatment, or have already received treatment within the last 5 years, with the following commercially available Terumo Aortic knitted and woven grafts and cardiovascular patches: * Gelsoft Plus - Straights and Bifurcated * Gelsoft Plus - Extra-Anatomical * Cardiovascular Patches - Gelseal, Gelsoft and Thin Wall * Gelweave - Abdominal, Thoracic and Thoracoabdominal * Gelweave - Valsalva This is a non-interventional study and therefore only patients who would normally receive treatment with a Terumo Aortic devices as part of standard treatment at the participating institution can be enrolled.
Who may be able to join
- Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study:
- All Patients:
- Patient meets the minimum age as per local regulations at time of consent
- Patient requires treatment with study device(s) according to the IFU(s)
- Patient is willing and able to comply with all SOC procedures and study visits
- Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively
Show all 11Show fewer
- For prospective emergency patients, retrospective consent is permissible
- For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed.
- Retrospective Patients only:
- Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death.
- Patient implant date is no more than 5 years prior to study start date.
Who cannot join
- Any patient who meets any of the following exclusion criteria will be excluded from participation in the study:
- Patient is unable or unwilling to comply with the SOC procedures or follow-up regime
- Patient is contraindicated per the device IFU
- Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure
Trial locations and contacts
30 sites in 6 countries. Contact the study team or a site near you to ask about taking part.
30 sites in 6 countries
United States10 sites, 10 recruiting
- Recruiting
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103
James Wu, James.Wu@lvhn.org
James Wu
- Recruiting
University of Colorado Anschutz
Aurora, Colorado, 80045
Brett Reece
Brett Reece
- Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Terence Semenec, terence.semenec@UHhospitals.org
Jae Cho
- Recruiting
Ohio State University
Columbus, Ohio, 43210
Kristine Orion
Kristine Orion
- Recruiting
Duke University
Durham, North Carolina, 27705
Chad Hughes, gchad.hughes@duke.edu
Chad Hughes
- Recruiting
East Carolina University
Greenville, North Carolina, 27858
Eddie Hill, Hille19@ecu.edu
Benjamin Degner
- Recruiting
Indiana University Health
Indianapolis, Indiana, 46202
Joel Corvera, MD, jcorvera@iuhealth.org
Joel Corvera
- Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, 19105
Eric Suchanec, Eric.Suchanec@Pennmedicine.upenn.edu
Nimesh Desai
- Recruiting
Virginia Commonwealth University
Richmond, Virginia, 23298
Daniel Newton, MD, daniel.newton@vcuhealth.org
Daniel Newton
- Recruiting
University of South Florida - Tampa General
Tampa, Florida, 33620
Thanh Tran, tqtran@usf.edu
Murray Shames
France8 sites, 6 recruiting
- Withdrawn
CHU Bordeaux
Bordeaux
- Recruiting
CHU Clermont Ferrand
Clermont-Ferrand
Valerie Batel, vbatel@chu-clermontferrand.fr
Thaveau
- Recruiting
CHU de Dijon
Dijon
Olivier Bouchot
Olivier Bouchot
- Recruiting
CHU de Lille
Lille, 59000
Mohamad Koussa
Mohamad Koussa
- Recruiting
Hôpital Nord Marseille
Marseille, 13015
Yves Alimi
Yves Alimi
- Withdrawn
CHU de Rennes
Rennes, 35033
- Recruiting
Hôpitaux Universitaires de Strasbourg - Hôpital Civil
Strasbourg, 67091
Nabil Chakfe
Nabil Chakfe
- Recruiting
CHU de Toulouse - Hôpital Rangueil
Toulouse, 31059
Xavier Chaufour
Xavier Chaufour
Germany7 sites, 7 recruiting
- Recruiting
Charité Berlin
Berlin, 12200
Irene Hinterseher, gefaesschirurgie@charite.de
Irene Hinterseher
- Recruiting
Uniklinik Bonn
Bonn, 53127
Marwan Hamiko, marwan.hamiko@ukbonn.de
Marwan Hamiko
- Recruiting
UNIVERSITÄTSKLINIKUM FREIBURG/Bad Krozingen
Freiburg im Breisgau
Gabriele Lechner, gabriele.lechner@uniklinik-freiburg.de
Martin Czerny
- Recruiting
UKE Hamburg
Hamburg, 20251
Sebastian Debus, s.debus@uke.de
Sebastian Debus
- Recruiting
Heart Center Leipzig
Leipzig
Michael Borger
Michael Borger
- Recruiting
Universitätsmedizin Mainz (University Hospital Mainz)
Mainz, 55131
Hazem El Beyrouti
Hazem El Beyrouti
- Recruiting
Ludwig-Maximilian Universität (LMU) Klinikum
Munich, 81377
Joscha Buch, joscha.buech@med.uni-muenchen.de
Sven Peterss
Belgium3 sites, 3 recruiting
- Recruiting
UZ Gent
Ghent, 9000
Nathalie Moreels, nathalie.moreels@uzgent.be
Nathalie Moreels
- Recruiting
AZ Groeninge Kortrijk
Kortrijk, 8500
Philip Lerut, philip.lerut@azgroeninge.be
Philip Lerut
- Recruiting
UZ Leuven
Leuven, 3000
Peter Verbrugghe, peter.verbrugghe@uzleuven.be
Peter Verbrugghe
Hungary1 site
- Completed
Semmelweis University Heart and Vascular Center
Budapest, Budapest, 1122
Netherlands1 site
- Active, not recruiting
Amphia Hospital (Ziekenhuis) Breda
Breda, 4818
About this study
Official title: A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice.
Data will be collected both retrospectively and prospectively.
- Conditions
- Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch
- Being tested
- Gelsoft Plus Vascular Graft, Vascular Bypass Graft, Cardiovascular Patch, Gelweave Vascular Graft, Gelweave Valsalva Vascular Graft
- Keywords
- Vascular Surgery
- Medical subject headings
- Aneurysm, Aortic Root Aneurysm, Dissection, Ascending Aorta, Carotid Artery Injuries, Aortic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gelsoft Plus Vascular GraftDevice
Also called Gelsoft Plus
Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
Vascular Bypass GraftDevice
Also called Gelsoft Plus Extra Anatomical
Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
Cardiovascular PatchDevice
Also called Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics
Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
Gelweave Vascular GraftDevice
Also called Gelweave
The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
Gelweave Valsalva Vascular GraftDevice
Also called Gelweave Valsalva
This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
| Study group | Role | What they receive |
|---|---|---|
| Gelsoft Plus - Straights and Bifurcated | Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards. Receives: Device: Gelsoft Plus Vascular Graft | |
| Gelsoft Plus - Extra-Anatomical | Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards. Receives: Device: Vascular Bypass Graft | |
| Cardiovascular Patches - Gelseal, Gelsoft, Thin Wall | Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards. Receives: Device: Cardiovascular Patch | |
| Gelweave - Abdominal, Thoracic, Thoracoabdominal | Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards:
* Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries.
* Thoracic aorta or arteries arising from the thoracic aorta.
* Abdominal and thoracic aorta requiring a thoracoabdominal repair Receives: Device: Gelweave Vascular Graft | |
| Gelweave - Valsalva | Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards. Receives: Device: Gelweave Valsalva Vascular Graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Operative Death
30 Day or In-Hospital Mortality
Measured: 1 Year
Graft Leakage
Device Failure: The presence of leakage or excessive bleeding through graft/patch
Measured: 1 Year
Secondary outcomes (3)
Device Endpoints
Device failures, requirement for reintervention or device related adverse events
Measured: 1 Year
Procedural Endpoints
Rifampicin or heparin soaking, procedure related adverse events
Measured: 1 Year
Safety Endpoints
Occurrence of the following: Mortality, Ischemia, Occlusion, Thrombosis, Haemmorrhage, Rupture, Pseudoaneurysm, Stroke
Measured: 1 Year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2020
- Study start17 Feb 2021
- Primary completionAug 2028 (estimated)
- Study completionJan 2037 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AneurysmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Vascutek Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04545502
- Sponsor's protocol ID
- PANTHER-001
- Acronym
- PANTHER
- Status last verified
- Aug 2026
- First submitted
- 3 Sep 2020
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No